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Abstract: The purpose of the present study was to investigate the biodistribution profile of the venom 
of Hemiscorpius lepturus, the most dangerous scorpion in Iran. Blood and tissue samples were taken at 
various predetermined intervals during a 400-minute period for the venom and a 360-minute period for 
the antivenom in rats. The radio-iodination was carried out using the chloramine-T method. The results 
showed that the descending order of venom uptake was skin, kidneys and intestine, respectively. The 
descending order of polyclonal antivenom uptake was kidneys, intestine, heart and lungs. The calculated 
pharmacokinetic parameters of the venom were Telimination half-life = 521.5 ± 12.6 minutes; Vd/F (apparent volume 
of distribution) = 14.9 ± 3.3 mL; clearance (CL/F, apparent total clearance of the drug from plasma) 0.02 ± 
0.005 mL/minute and for the antivenom Telimination half-life = 113.7 ± 7.4 minutes; Vd/F = 13 ± 1.2 mL and CL/F 
0.08 ± 0.01 mL/minute. The pharmacokinetics profile comparison of the venom with that of the antivenom 
shows that serotherapy may be more effective if administered within 2-4 hours following envenomation 
by H. lepturus.
Key words: Hemiscorpius lepturus scorpion venom, polyvalent antivenom, pharmacokinetic parameters, 
tissue distribution. 
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INTRODUCTION
Envenomation by various species of scorpions 
is a serious public health issue in many regions of 
the world. In Iran, so far 24 species of scorpions 
have been identified, 12 of which are found in the 
Khuzestan province in the southwest region of 
this country (1). The medically relevant species 
found in this region are Androctonus crassicauda, 
Mesobuthus eupeus and Hemiscorpius lepturus. 
Unlike the first two, which belong to Buthidae 
family and produce sympathomimetic and 
parasympathetic overstimulation, the latter is 
a member of Scorpionidae family (subfamily 
Hemiscorpiidae), the most venomous of all types 
of scorpions, contributing to 95% of scorpion-
associated mortalities (2-4). Dermonecrotic 
reactions, anemia, hemolysis, renal failure, 
cardiovascular and central nervous system 
disorders are usual clinical manifestations of 
envenomation by this scorpion (2, 3, 5). 
A specific polyvalent antivenom is produced 
by the Razi Vaccine and Serum Research Institute 
through the immunization of horses against 
the six medically relevant scorpion species in 
Iran: Odontobuthus doriae, Mesobuthus eupeus, 
Androctonus crassicauda, Buthotus saulcyi, 
Buthotus sach and H. lepturus (6). Immunotherapy 
by polyvalent antivenom produced by the Razi 
Institute of Iran is the conventional treatment 
for envenomation caused by H. lepturus, though 
the efficacy of such treatment by intravenous 
route is controversial. Envenomed patients by 
this scorpion are usually treated by intravenous 
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administration of antivenom. Nevertheless, 
there is disagreement among physicians on 
the best way to neutralize the toxic effects of 
envenomation and the correct time for antivenom 
administration (7). It has been generally accepted 
that the ideal antivenom must reach the different 
tissues in which the venom produces its toxic 
effects and once bonded the complex must 
be rapidly eliminated (8). As a whole, there is 
no general consensus about the dose, route of 
administration and its effectiveness in treating 
human envenomation by this scorpion. 
International pharmaceutical regulations 
recommend pharmacokinetic studies concerning 
the drugs to be used by humans in order to 
evaluate their safety and the appropriate dosage. 
In summary, pharmacokinetics contributes to 
the understanding of the relationship between 
dose and response in the design of new therapies 
and/or modifications of the current medicinal 
products. 
Labeled antivenoms have been used in 
biodistribution and pharmacokinetics studies 
for determining the efficacy of the antivenom. 
These studies were done with antivenom 
labeled with 125I (9, 10). Previous experimental 
pharmacokinetic studies employed radiolabeling 
techniques to show the pharmacokinetics of 
Androctonus amoreuxi, Leiurus quinquestriatus, 
Buthotus judaicus and Androctonus crassicauda 
venoms (11-13). 
Despite well known severe toxic manifestations, 
no pharmacokinetic study has been previously 
carried out on the venom of H. lepturus. 
Intravenous (IV) administration of the available 
antivenom is normally prescribed by physicians 
for the treatment of H. lepturus envenomation. 
This toxicokinetic study, therefore, was designed 
to evaluate the pharmacokinetic parameters 
of the venom and the available polyvalent 
antivenom. For this purpose, a protocol was 
selected to closely simulate human accidental 
envenomation and its distribution in various 
body tissues was determined in Sprague Dawley 
rats.  Trichloroacetic acid (TCA), precipitated 
radiolabeled venom and antivenom were 
employed in the study and pharmacokinetic 
parameters of the raw venom of H. lepturus (after 
subcutaneous administration) and Razi Institute 
polyvalent antivenom (via intravenous route) 
were also evaluated. 
MATERIALS AND METHODS
Animals
Sprague Dawley rats (100 to 150 g body 
weight) were used in this experiment. The rats 
were purchased from Shaheed Beheshti Breeding 
Laboratories and housed in groups of three in 
PVC cages with free access to tap water and hard 
food pellets. They were kept at 23 ± 2°C, and 
maintained at a 12-hour light/dark cycle, starting 
at 7 am.
Materials 
The lyophilized venom was prepared from 
electrically stimulated telson of H. lepturus 
collected during summer in the Khuzestan 
province. The polyvalent scorpion antivenom 
(ampoules of 5 mL stored at 2 to 8°C) was provided 
by the the Razi Institute and the Hesarak Karaj 
facilty in Iran. This product is a pepsin-digested, 
refined and concentrated preparation obtained 
from equine hyperimmune serum (6) ). The final 
antivenom is adjusted to contain the desired 
neutralizing antibody titer in about 10.3 mg of 
protein/mL. The pH was adjusted to 6.4.  
Sodium iodine Na125I (specific activity = 0.2 
mCi/µL of iodide), chloramine-T and sodium 
metabisulfite were purchased from Sigma-
Aldrich Co (USA) and Sephadex G-50 column 
was provided by Pharmacia (Sweden).
Labeling of H. lepturus Venom and Polyvalent 
Antivenon
H. lepturus venom was radioiodinated 
using the chloramine-T method as previously 
described (14) with some modifications. The 
reaction was initiated by addition of 10 µL (5mg/
mL)  chloramine-T solution – prepared in a 
0.05 M sodium phosphate buffer (pH 7.6) – to 
10 µL of aqueous solution of lyophilized venom 
in distilled water (1 mg/mL) mixed with 10 µL 
of 125I-Na solution (2 mCi). After one minute, 
the reaction was stopped using 10 µL of a 5 mg/
mL sodium metabisulfite. All the unbound [125I] 
iodide was displaced by addition of 100 µL of 
potassium iodide (100 mg/mL). 125I-venom 
was separated from free iodine by gel filtration 
through a Sephadex G50 column equilibrated with 
PBS, pH 7.4, 30 mL/hour. Radiolabeled fragment 
was collected sequentially (1 mL) by loading with 
PBS and its radioactivity assessed by gamma 
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counter. Six samples with greatest radioactivity 
were separated and used in the experiment. 
To determine the pharmacokinetics of 
radiolabeled Razi Institute polyvalent antivenom 
in the envenomed rats, 300 µL were added to 
the same volume of phosphate buffer solution. 
Subsequently, 300 µL of the mixture were removed 
and the radiolabeling method was performed 
similar to that in the previous experiment. After 
labeling, radiolabeled venom and antivenom were 
kept at 4°C until the time of use. The antivenom 
contained a dilution of the F (ab´) 2 fraction of 
equine immunoglobulins obtained after double 
saline precipitation and pepsin digestion. The 
mean protein content of the antivenom from the 
used batches was 3.6 mg/mL, with a neutralizing 
ability of 26 LD50/mL. The specific radioactivity 
of the substrates (venom and antivenom) was 
approximately 220000 cpm/mg protein (cpm: 
count per minute).
Animal Experiments
On the day of the experiment, 0.2 mL of 
the labeled H. lepturus venom and polyvalent 
antivenom solution were injected subcutaneously 
and intravenously, respectively, in separate 
experiments to seven groups of rats (n = 3). 
Subcutaneous injections of the venom were 
administered to the gluteal region and all 
antivenom injections were performed from tail 
vein. Animals (three for each time point) were 
euthanized with carbon dioxide 10, 40, 60, 120, 
240, 360 and 400 minutes (for venom) and 5, 10, 
40, 60, 120, 240 and 360 minutes (for polyvalent 
antivenom) post injection, to determine the 
distribution of radiolabeled compounds in blood 
and internal organs. 
The blood was obtained from the heart  after 
euthanasia. The organs were deposited in separate 
pre-weighed disposable tubes. Selected organs 
plus the skin at the site of venom injection were 
weighed, and their radioactivity was measured by 
the nucleus automatic well-type γ-counter (Model 
600 B, Gammatec II, INC, Oakridge). The skin 
from the site of injection was used to determine 
the radioactivity percent. A 2-centimeter incision 
(diameter) was made to the skin at the inoculated 
site in order to determine radioactivity/gram. At 
least two standards of the injected material were 
set aside and counted at the same time to correct 
for physical decay of [125I]. The percent of the 
injected dose (based on the radioactivity count) 
per organ weight (%ID/g) was determined. Rat 
blood density (1.05) was used for calculation of 
percent of initial count per milliliter of blood 
to determine pharmacokinetic parameters 
of the venom and antivenom (15).  The Ethic 
Committee of the Jundishapur University, Ahvaz 
approved of the design of the experiment, and 
the protocol conforms to the guidelines of the 
National Institutes of Health (NIH).
Determination of Pharmacokinetic 
Parameters 
The sparse radioactive counts per milliliter of 
blood data relative to the initial count versus time 
were fitted to a one-compartment open model 
after an IV bolus dose for antivenom and to a 
one-compartment open model with first-order 
absorption for venom using a non-linear mixed 
effects modeling approach. Exponential and 
additive error models were used to describe inter- 
and intra- animal variability, respectively. The 
modeling was done using Monolix 3.1 software 
(16). 
Statistical Analysis 
The biodistribution of venom and antivenom 
were presented as mean ± standard deviation. The 
means were calculated from at least three separate 
experiments. Pharmacokinetic parameters were 
expressed as mean ± SEM. The significance of 
the data between two groups was analyzed by 
the Paired Students’ t-test. Statistical comparison 
between groups was made by one-way ANOVA. 
The level of significance was set at p < 0.05. 
RESULTS
Radiolabeled Venom Distribution
The distribution profile of the radiolabeled 
venom in nine different organs during the 
experimental period of 400 minutes is shown 
in Table 1. In addition, the trend of change 
in concentration of the venom in four main 
organs where the venom was mostly distributed 
(blood, kidneys, intestine and brain) and the 
absorption from the site of injection is illustrated 
in Figure 1 and 2, respectively. Ten minutes 
after subcutaneous administration, the highest 
radioactivity was measured in the skin followed 
by the kidneys and intestine. Although the initial 
concentration of the venom in the intestine was 
lower than that measured in the kidneys, after 
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60 minutes their levels of distribution were very 
similar. The highest measured radioactivity in the 
small intestine at 60 minutes was 3.91%ID/g and 
at 400 minutes its concentration reached 1.23. 
The level of radioactivity reached its peak 
in the blood (7.86% ID/g) after 120 minutes 
and then decreased slowly. However, after 400 
minutes the radioactivity of the venom in the 
blood was still higher than in other organs except 
the skin and equaled that of the kidneys. A much 
lower concentration was found to be distributed 
in other organs such as bones, lungs, muscles, and 
heart. Among these organs, the main site was the 
brain. This site reached its peak at 120 minutes. 
Such time interval, 120 minutes, is correlated 
with the maximum plasma radioactivity/gram 
and dropped to 0.94ID/g after 400 minutes.  
The radioactivity of the blood was significantly 
elevated and subjected to definitive changes 
within 10-40 minutes compared with that of the 
beginning of the experiment (p < 0.001). This 
amount remained without a significant change 
for 120 minutes (120-240 minutes following 
venom administration (Table  1). 
Absorption of the venom from the injection 
site was relatively quick after subcutaneous 
injection, with a rapid initial phase that lasted 
60 minutes, followed by a slight decline. After 60 
minutes until the end of the experimental period 
(400 minutes) the venom concentration at the 
injection site remained almost constant (Figure 
2). The means of measured radioactivity reflect 
Figure 1. Distribution of the venom after 
subcutaneous injection in various organs in rats. 
Values are the averages obtained from three rats 
in each group. The times shown represent intervals 
following venom administration (125I-labeled 10 µg 
venom per rat).
Table 1. Biodistribution of subcutaneously injected [125I] H. lepturus venom in rat expressed as percentage 
of radioactivity/gram of the tissue (mean ± SD; n = 3) upon time (minutes). The times shown represent 
intervals following administration (10 µg 125I-labeled venom per rat)
10 min. 40 min. 60 min. 120 min. 240 min. 360 min. 400 min. Mean 
Blood 1.63 ± 0.32
3.52 ± 
0.7
4.32 ± 
1.1
7.86 ± 
1.56
6.7 ± 
1.23
3.35 ± 
0.63
2.1 ± 
0.36 4.21
Kidneys 5.1 ± 0.64
5.14 ± 
1.02
4.3 ± 
0.37
3.93 ± 
0.87
3.36 ± 
0.43
2.42 ± 
0.82
2.24 ± 
0.32 3.78
Skin 27.2 ± 3.21
17.7 ± 
2.32
6.65 ± 
1.83
5.56 ± 
1.27
5.12 ± 
1.47
4.32 ± 
0.32
4.12 ± 
0.62 10.09*
Brain 0.84 ± 0.26
1.42 ± 
0.67
1.84 ± 
0.12
2.29 ± 
0.67
1.94 ± 
0.79
1.26 ± 
0.38
0.94 ± 
0.32 1.5 
Heart 0.02 0.03 0.03 0.02 0.01 0.01 0.01 –
Lungs 0.02 0.03 0.03 0.04 0.03 0.02 0.01 –
Muscles 0.01 0.01 0.02 0.02 0.02 0.02 0.01 –
Intestine 2.51 ± 0.26
3.7 ± 
0.05
3.91 ± 
0.21
3.85 ± 
0.31
3.02 ± 
0.32
2.14 ± 
0.04
1.23 ± 
0.32 2.9
Femur 0.01 0.02 0.02 0.02 0.01 0.01 0.01
Sum 37.34 31.57 20.93 25.57 20.2 13.55 10.67
* A 2-cm diameter incision was made at the inoculation site in order to determine radioactivity/gram.
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the presence of the toxins in the tissues during the 
period of the study. The highest measured mean 
radioactivity was in the skin (10.09 radioactivity/
gram of the tissue), followed by the blood (4.21), 
kidneys (3.78) and intestine (2.9), respectively.
Analysis of the pharmacokinetic data showed 
that the elimination-half life T1/2 of the venom 
was 521 minutes. The value of Vd/F for the venom 
and its apparent total body clearance (CL/F) rate 
were 14.9 mL and 0.02 mL/minute, respectively 
(Table 2). 
Distribution of Radiolabeled Antivenom in 
Rats
The mean ± SD values of distribution in various 
organs after intravenous administration of 0.2 
mL of radiolabeled polyclonal antivenom are 
shown in Table 3. High amounts of radioactivity 
were detected in the blood (21.42%ID/g) and 
kidneys (19.56%ID/g) at five minutes post 
intravenous injection. Radioactivity measured 
in other organs during the study period of 360 
minutes was more significant than the venom 
in the intestine (6.74%ID/g), brain (3.21%ID/g), 
heart (10.52%ID/g) and lungs (11.65% ID/g) 
at five minutes (p < 0.05) (Table 3). Antivenom 
reached its maximum level in the heart and brain 
within five minutes following administration. 
Peak level in heart declined significantly (p < 
0.001) and rapidly within five minutes during 5 
to 10 minutes following administration. After ten 
minutes, the antivenom level in the heart declined 
gradually until the end of the period of the study. 
Antivenom reached its highest concentration 
only five minutes following administration. Peak 
concentration of antivenom in the blood declined 
significantly (p < 0.001) within five minutes 
following administration. Antivenom level in the 
intestine was higher than the blood concentration 
during 40 to 240 minutes following antivenom 
administration. 
The level of radioactivity reached its peak in 
the brain (3.21%ID/g) after five minutes and 
then declined gradually during 360 minutes. The 
rate of decline of the radioactivity in the kidneys 
was well correlated with that in the blood. The 
rate of decline of the radioactivity in the brain 
was almost similar to that in the blood. The 
maximum radioactivity in muscles and intestine 
were achieved at delayed times 40 and 60 minutes, 
respectively when the blood concentration had 
already declined. After 40 minutes, the antivenom 
Figure 2. Distribution of H. lepturus venom in the 
skin after subcutaneous injection in rats. Values are 
the averages obtained from three rats in each group. 
The times shown represent intervals following 
venom administration (125 I-labeled 10 µg venom 
per rat).
Table 2. Pharmacokinetic parameters of 125I-radiolabeled H. lepturus venom and its multivalent antivenom. 
Ten microgram of H. lepturus venom and 0.2 mL of antivenom were administered via subcutaneous (SC) 
and intravenous (IV), respectively
Parameters Venom (SC) Antivenom(IV)
Vd/Fa,b (mL) 14.9 ± 3.3 13.0 ± 1.2
CL/Fb,c (mL/min) 0.02 ± 0.005 0.08 ± 0.01
Kad (1/min) 0.04 ± 0.02 –
t1/2e (min) 521.5 ± 12.6 113.7 ± 7.4
aApparent volume of distribution. bFor intravenous administration of venom, its bioavailability (F) is equal to 1. cTotal (apparent, in 
case of venom) systemic clearance. dFirst order absorption constant. eElimination half-life
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amount in the intestine was higher than in the 
kidneys. The mean measure of radioactivity 
reflects the presence of the antivenom in the 
tissues during the whole period of the study. The 
highest measured mean of radioactivity was in 
the blood (7.61 radioactivity/gram of the tissue), 
followed by the kidneys (6.92), intestine (6.5) and 
heart (3.64), respectively (Table 3). 
The measured pharmacokinetic parameters 
showed that half-life of the antivenom was 113.7 
minutes, with Vd/F and apparent clearance of 
13 mL and 0.08 mL/minute, respectively (Table 
2). Statistical analyses of biodistribution values 
of venom and antivenom showed a significant 
difference in all investigated organs at different 
time intervals. These differences are distinctive 
especially for heart, lungs and muscles (Table 1 
and 3).
DISCUSSION
Scorpion sting mortality in Iran is mostly 
due to H. lepturus, thus it can be stated that this 
creature is the most dangerous scorpion of this 
country (4). Development of severe forms of 
intoxication and regular reports of treatment 
failure following accidental H. lepturus scorpion 
envenomation, especially among children and in 
late referral in adults, is a common occurrence. 
One underlying reason is the lack of knowledge 
of the pharmacokinetic parameters of the venom 
for this scorpion. Therefore, the aim of this study 
was to clarify the pharmacokinetic parameters 
of this venom and that of its available antivenom 
allowing for the most appropriate form of 
treatment to be given to envenomed patients.  
In this study, we report, for the first time, the 
biodistribution profile of the venom of H. lepturus 
and its available antivenom, using chloramine-T 
method according to previous experiments (17). 
As to drug administration, 10 µg of H. lepturus 
venom and 0.2 of mL antivenom were given 
via SC and IV route, respectively. The selected 
dose of venom was the average amount secreted 
by a scorpion sting. The amount of antivenom 
administered to the rats was calculated taking 
into account their body weight in relation to the 
standard dose of 10 mL given to human subjects. 
Due to limitations of earlier sampling, i.e. less 
than five minutes, any attempt to fit two or three 
compartment models were not successful. 
As shown, the volume of distribution of 
antivenom was 14.9 mL which is not different 
compared to the Vd/F of venom (13 mL). 
Table 3. Biodistribution of intravenously injected [125I] Razi Institute antivenom in rat expressed as percentage 
of radioactivity/gram of tissue (mean ± SD; n = 3) upon time (minutes). The times shown represent intervals 
following administration (0.2 mL 125 I-labeled antivenom per rat)
5 min. 10 min. 40 min. 60 min. 120 min. 240 min. 360 min. Mean
Blood 21.42 ± 3.4
8.84 ± 
1.67
6.35 ± 
1.92
5.42 ± 
1.34
4.31 ± 
0.93
3.82 ± 
0.63
3.12 ± 
0.46 7.61
Kidneys 19.56 ± 3.42
7.75 ± 
2.02
6.32 ± 
1.37
5.34 ± 
1.87
4.28 ± 
1.43
3.32 ± 
0.82
1.89 ± 
0.32 6.92
Intestine 6.74 ± 1.26
7.23 ± 
1.5
8.36 ± 
1.21
9.52 ± 
1.69
6.46 ± 
1.32 4.36 ± 1.4
2.83 ± 
1.35 6.5
Brain 3.21 ± 0.82
2.82 ± 
0.63
2.13 ± 
0.48
1.87 ± 
0.32
1.12 ± 
0.21 0.62 ± 0.1
0.31 ± 
0.11 1.72
Heart 10.52 ± 2.21
3.89 ± 
1.12
3.61 ± 
0.92
3.12 ± 
0.84
1.86 ± 
0.53
1.54 ± 
0.36
0.98 ± 
0.32 3.64
Lungs 11.65 ± 2.24
4.45 ± 
1.53
3.86 ± 
1.21
3.52 ± 
0.75
2.41 ± 
0.45
2.14 ± 
0.67
1.36 ± 
0.65 4.19
Muscles 1.31 ± 0.64
1.65 ± 
0.32
2.34 ± 
0.48
1.97 ± 
0.39
1.47 ± 
0.37
0.94 ± 
0.21 0.38 ± 0.1 1.43
Femur 0.82 ± 0.21
1.17 ± 
0.39
2.1 ± 
0.37
2.23 ± 
0.67
1.82 ± 
0.42
1.12 ± 
0.35
0.73 ± 
0.23 1.42
Sum 64.71 37.75 35.07 32.99 23.72 16.97 11.6
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Considering the venom concentration in the 
blood, the venom was absorbed and reached 
its maximum at 120 minutes. We found a rapid 
increase in the measured concentration of the 
venom during the 60 to 120 minutes (Table 1), 
especially in the blood. The volume of distribution 
of this venom was 15 mL, which was different 
from previous studies. The apparent volume of 
distribution of other studied venoms is different 
(11, 13, 18-21). 
After tracer administration (labeled venom 
with iodine) the pattern of plasma radioactivity 
is different under the same conditions to yield 
a maximum peak.  The route of administration 
had a major influence on the time for maximum 
plasma radioactivity. The Tmax was longer than 
those reported for venoms such as Andercotonus 
australis hector (21), Tityus serrulatus (18), 
Centruroides limpidus limpidus (19), Androctonus 
mauretanicus mauretanicus (20) and shorter 
lower than those reported by Ismail and Abd-
Elsalam in 1988 (12). The underlying reason for 
such discrepancies in the results may be due to the 
route of administration and pharmacokinetics of 
scorpion venom and animal model used, or due 
to differences in the quantifying methods used 
(radioactivity versus ELISA). 
The clearance of H. lepturus venom (0.02 mL/
minute) was lower than Odonthubuthus doriae 
(2.12 mL/minute). The gradual absorption and 
distribution of the H. lepturus venom when 
compared with that of O. doriae indicate that 
H. lepturus venom has a slower biodistribution. 
This finding may be related to the delayed clinical 
manifestations of the envenomation by this 
scorpion (3, 22). 
The elimination of venom is quite slow, as could 
be observed from the small value of its clearance 
and long elimination half life. These facts could 
clearly explain the prolonged adverse effects of the 
venom. It is important to note that intravenous 
administration results in a fast neutralizing 
efficacy compared to the intramuscular route 
(13). Based on the data (Table 1), it is reasonable 
to suggest that if a neutralizing dose of antivenom 
is infused over a period of 120 to 240 minutes 
following sting, more neutralization of toxicity 
is likely to occur. This is advisable in order to 
compensate for the slow rate of distribution of 
venom in tissue compartments.  
Comparison of the measured biodistribution 
values of venom and antivenom showed 
distinguishing differences in all organs at different 
time intervals especially for the heart, lungs and 
muscles. 
Based on the results, the amount of 
radiolabeled venom at the site of injection (skin) 
was very high in comparison to other organs. 
Radioactivity of all tissues together at ten minutes 
was around 37.34% and skin contained around 
27.2% of injected counts, but after 40 minutes its 
percentage was 17.7%. The reason for consistent 
presence of the venom at the injection site of skin 
may be due to two possible mechanisms: firstly, 
the venom is bound to underlying skin layers or is 
taken up by cells within this layer. This suggestion 
has clinical implications since patients stung by 
this scorpion develop necrotic skin reactions 
that gradually become more severe, and require 
surgical debridement. If this assumption is true, 
then early removal of the skin at the sting site may 
be helpful. Secondly, the measured radioactivity 
is not due to the toxin, but its degraded products 
are indistinguishably counted by our radioactivity 
method of measurement. About 7% of the total 
initial activity could be detected at the site of 
injection one hour after the administration. Thus 
it can be inferred that the skin is not a major 
depot site of the venom and hence the late toxic 
effects of the venom could be related to its slow 
elimination from the body. 
In order to confirm either of these suggestions, 
ELISA method needs to be carried out with the 
specific H. lepturus toxin. In order to make more 
accurate estimation of our findings, radiolabeled 
albumin method will need to be carried out in 
future studies (23). The radioactivity uptake in 
the small intestine increased until 60 minutes 
(3.91%ID/g) and then decreased slowly. The 
radioactivity uptake in the small intestine showed 
a smaller fraction than the kidneys. These data 
may indicate that hepatobilliary secretion of this 
venom plays a less important role than the kidneys 
in elimination from the body. At ten minutes, the 
highest radioactivity was measured in the kidneys 
followed by intestine suggesting that the venom 
is primarily and rapidly eliminated by the renal 
and hepatic (as reflected by its detection in the 
intestine) systems. 
The overall radioactivity level rate of decrease 
of the venom was slow during the 10 to 60 minutes 
following administration. So we can conclude that 
the kidneys showed high radioactivity at times 
where the blood radioactivity was lower (12). 
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The identified radioactivity in the kidneys can be 
associated with partial elimination or secretion of 
H. lepturus venom to renal tubules. The consistent 
presence of the venom in the renal system during 
the period of study suggest that the renal system 
is the target organ in which the venom causes 
direct toxicity, as has been commonly reported in 
patients. 
The gradual increase of venom in plasma and its 
peaking at 120 minutes with more gradual decline 
suggest that venom has a relatively prolonged 
contact with blood cells. Previous clinical 
and experimental results have demonstrated 
hemolytic characteristics of this venom. The 
renal toxicity seems to be compounded by RBC 
hemolysis as well as the persistent presence of the 
venom. Accumulation of venom in other organs 
like heart and brain was very low compared with 
other organs, so it seems that venom concentration 
is not directly responsible for all manifestations 
of envenomation like seizure, tachycardia and 
arrhythmia (3).
The complex mathematical formulas used in 
explaining the pharmacokinetics of a given agent, 
despite being useful and essential for planning 
treatment protocols, are merely reflecting 
approximations of the trends and normally used 
to express the changes by computational and 
exponential terms. The obtained data cannot 
fully explain the underlying reasons for the 
delayed and devastating toxic ministrations 
seen in patients stung by this scorpion, who 
do not feel pain and do not show immediate 
symptomatic manifestations. In order to explain 
these discrepancies, we need to look more closely 
to the general distribution profiles of the venom 
in these tissues, especially the skin, intestine and 
kidneys.  
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